Categories: Health

Financire de Tubize – 2025 half-year financial report

 | Source: Financière de Tubize SA

Half-year financial report 2025
Regulated information 2 August 2025

The board of directors of Financière de Tubize has established the 2025 half-year report. This report is available on the website www.financiere-tubize.be.

  • Profit for the first half of 2025: € 95.6 million (€ 92.9 million in 2024, + 2.8%),
  • Dividend received from UCB: € 98.1 million (€ 1.39 per share, an increase of 2.2% compared to the previous year),
  • 2024 Dividend paid to Financière de Tubize’s shareholders in 2025 of € 46.3 million (€ 1.04 per share, an increase of 7.22% compared to the previous year),
  • Acquisition, in 2025, of 24,487 UCB shares, for a total amount of € 4.37 million, at an average price of € 178.3. Our stake in UCB has increased from 36.27% on 31 December 2024 to 36,28% on 30 June 2025,
  • Decrease of outstanding bank borrowings from € 41.3 million at 31 December 2024 to € nil at 30 June 2025.
GlobeNews Wire

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

4 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

4 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

4 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

4 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

4 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

4 hours ago